| Title |
Pharmacological management of acute bronchiolitis
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, October 2008
|
| DOI | 10.2147/tcrm.s1556 |
| Pubmed ID | |
| Authors |
Melvin Wright, Charles J Mullett, Giovanni Piedimonte |
| Abstract |
This article reviews the current knowledge base related to the pharmacological treatments for acute bronchiolitis. Bronchiolitis is a common lower respiratory illness affecting infants worldwide. The mainstays of therapy include airway support, supplemental oxygen, and support of fluids and nutrition. Frequently tried pharmacological interventions, such as ribavirin, nebulized bronchodilators, and systemic corticosteroids, have not been proven to benefit patients with bronchiolitis. Antibiotics do not improve the clinical course of patients with bronchiolitis, and should be used only in those patients with proven concurrent bacterial infection. Exogenous surfactant and heliox therapy also cannot be recommended for routine use, but surfactant replacement holds promise and should be further studied. |
Mendeley readers
The data shown below were compiled from readership statistics for 52 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 2% |
| Egypt | 1 | 2% |
| Unknown | 50 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 8 | 15% |
| Student > Postgraduate | 7 | 13% |
| Student > Master | 6 | 12% |
| Student > Doctoral Student | 4 | 8% |
| Student > Ph. D. Student | 4 | 8% |
| Other | 13 | 25% |
| Unknown | 10 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 22 | 42% |
| Nursing and Health Professions | 6 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 8% |
| Chemical Engineering | 1 | 2% |
| Immunology and Microbiology | 1 | 2% |
| Other | 3 | 6% |
| Unknown | 15 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 March 2017.
All research outputs
#8,534,528
of 25,373,627 outputs
Outputs from Therapeutics and Clinical Risk Management
#461
of 1,323 outputs
Outputs of similar age
#36,704
of 101,351 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#6
of 13 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has gotten more attention than average, scoring higher than 55% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 101,351 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.